Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study)
EBioMedicine. 2024 Dec 6:105492. doi: 10.1016/j.ebiom.2024.105492. Online ahead of print. ABSTRACT BACKGROUND: Evidence from preclinical studies in small and large animal models has shown neuroprotective …